CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria: must fulfill with all the items below

* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.
* \>=20 years old.
* had pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that was recurrent or metastatic and not curable by local therapy.
* had at least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
* Medical records during treatment are available.

Exclusion Criteria:

* Medical records during treatment unavailable
* Could not cooperate with blood sampling
* Without informed consent

主要终点：Progression-free survival (PFS) · The time from diagnosis as non-curable disease to clinically (physical examination or radiographically) confirmed disease progression or death from any cause, whichever came first. · From enrollment to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
次要终点：Overall survival (OS)

• Recurrent/Metastatic squamous cell carcinoma of the head and neck · Patient inclusion criteria, must fulfill with all the items below 1\. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.\>=20 years old. 3\. had pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that was recurrent or metastatic and not curable by local therapy. 4\. had at least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 5. Medical records during treatment are available.

The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different treatment modalities and drugs. The main questions it aims to answer are: 1. Investigators plan to correlate circulating tumor cells (CTC), circulating tumor emboli (CTM), and the composition of NK cells in CTM with clinical outcomes and establish their association with patient prognosis. 2. Investigators plan to understand the composition of NK cells and the immune cell components within CTM, and correlate these findings with treatment efficacy. Patients with recurrent/metastatic head and neck cancer will be included after informed consent and investigators will collect blood samples for analysis from them under the treatment provided by their primary care physicians.